keyword
MENU ▼
Read by QxMD icon Read
search

Vmat2

keyword
https://www.readbyqxmd.com/read/29338466/valbenazine-as-the-first-and-only-approved-treatment-for-adults-with-tardive-dyskinesia
#1
Harini Sarva, Claire Henchcliffe
Valbenazine is a selective VMAT2 inhibitor that the FDA approved in April 2017 for the specific treatment of tardive dyskinesia (TD), a movement disorder commonly caused by dopamine blocking agents. Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. Areas covered: This drug profile reviews the development of valbenazine and the clinical trials that led to its approval as the first treatment specific to TD. The literature search was performed with the PubMed online database...
January 17, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29337277/compensatory-dopaminergic-cholinergic-interactions-in-conflict-processing-evidence-from-patients-with-parkinson-s-disease
#2
REVIEW
Kamin Kim, Nicolaas I Bohnen, Martijn L T M Müller, Cindy Lustig
Executive functions are complex both in the cognitive operations involved and in the neural structures and functions that support those operations. This complexity makes executive function highly vulnerable to the detrimental effects of aging, brain injury, and disease, but may also open paths to compensation. Neural compensation is often used to explain findings of additional or altered patterns of brain activations by older adults or patient populations compared to young adults or healthy controls, especially when associated with relatively preserved performance...
January 11, 2018: NeuroImage
https://www.readbyqxmd.com/read/29306111/deuterated-18f-9-o-hexadeutero-3-fluoropropoxyl-dihydrotetrabenazine-d6-fp-dtbz-a-vesicular-monoamine-transporter-2-vmat2-imaging-agent
#3
Futao Liu, Seok Rye Choi, Zhihao Zha, Karl Ploessl, Lin Zhu, Hank F Kung
INTRODUCTION: Vesicular monoamine transporters 2 (VMAT2) in the brain serve as transporter for packaging monoamine in vesicles for normal CNS neurotransmission. Several VMAT2 imaging agents, [11C]-(+)-DTBZ, dihydrotetrabenazine and [18F]FP-(+)-DTBZ (9-O-fluoropropyl-(+)-dihydro tetrabenazine, a.k.a. [18F]AV-133), are useful for studying the changes in brain function related to monoamine transmission by in vivo imaging. Deuterated analogs have been reported targeting VMAT2 binding sites...
December 6, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29281252/toward-serotonin-fluorescent-false-neurotransmitters-development-of-fluorescent-dual-serotonin-and-vesicular-monoamine-transporter-substrates-for-visualizing-serotonin-neurons
#4
Adam Henke, Yekaterina Kovalyova, Matthew Dunn, Dominik Dreier, Niko G Gubernator, Iva Dincheva, Christopher Hwu, Peter Sebej, Mark S Ansorge, David Sulzer, Dalibor Sames
Ongoing efforts in our laboratories focus on design of optical reporters known as fluorescent false neurotransmitters (FFNs) that enable the visualization of uptake into, packaging within, and release from individual monoaminergic neurons and presynaptic sites in the brain. Here, we introduce the molecular probe FFN246 as an expansion of the FFN platform to the serotonergic system. Combining the acridone fluorophore with the ethylamine recognition element of serotonin, we identified FFN54 and FFN246 as substrates for both the serotonin transporter and the vesicular monoamine transporter 2 (VMAT2)...
December 27, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29249207/mechanism-of-action-of-vesicular-monoamine-transporter-2-vmat2-inhibitors-in-tardive-dyskinesia-reducing-dopamine-leads-to-less-go-and-more-stop-from-the-motor-striatum-for-robust-therapeutic-effects
#5
Stephen M Stahl
Tardive dyskinesia can now be successfully treated by inhibiting the vesicular monoamine transporter type 2 (VMAT2).
December 18, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29246613/clinical-management-of-tardive-dyskinesia-five-steps-to-success
#6
REVIEW
Leslie Citrome
Tardive dyskinesia (TD) has long been thought to be a generally irreversible consequence of the use of dopamine receptor blocking agents. There is now an opportunity to successfully manage this condition with agents approved by the US Food and Drug Administration. This is important because TD has not been eliminated with the use of second-generation antipsychotics, and the expansion of antipsychotics to treat conditions other than schizophrenia has resulted in millions of additional individuals at risk for developing TD...
December 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29233657/pcb95-and-pcb153-change-dopamine-levels-and-turn-over-in-pc12-cells
#7
Sabah H Enayah, Brigitte C Vanle, Laurence J Fuortes, Jonathan A Doorn, Gabriele Ludewig
Polychlorinated biphenyls (PCB) exposure at low chronic levels is a significant public health concern. Animal and epidemiological studies indicate that low PCB body burden may cause neurotoxicity and be a risk factor for neurodegenerative diseases. In the current study, we measured the ability of two non-dioxin like PCBs, 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153) and 2,2'3,5',6-pentachlorobiphenyl (PCB95), to alter dopamine (DA) levels and metabolism using the dopaminergic PC12 cell line. Our hypothesis is that treatment of PC12 cells with non-toxic concentrations of PCB153 or PCB95 for 12 and 24h will have different effects due to different congener structures...
December 9, 2017: Toxicology
https://www.readbyqxmd.com/read/29207913/generation-of-dopamine-secreting-cells-from-human-adipose-tissue-derived-stem-cells-in-vitro
#8
Mohammad Hasan Soheilifar, Arash Javeri, Hossein Amini, Masoumeh Fakhr Taha
Several studies have demonstrated the differentiation of human adipose tissue-derived stem cells (hADSCs) to neuronal and glial phenotypes, but directing the fate of these cells toward dopaminergic neurons has not been frequently reported. The aim of the present study was to investigate dopaminergic specification of hADSCs in vitro. ADSCs were isolated from subcutaneous abdominal adipose tissue and were characterized. For dopaminergic differentiation, a cocktail of sonic hedgehog, fibroblast growth factor 8, basic fibroblast growth factor and brain-derived neurotrophic factor were used under a low serum condition...
December 5, 2017: Rejuvenation Research
https://www.readbyqxmd.com/read/29185481/methamphetamine-induces-dopamine-release-in-the-nucleus-accumbens-through-a-sigma-receptor-mediated-pathway
#9
David M Hedges, J Daniel Obray, Jordan T Yorgason, Eun Young Jang, Vajira K Weerasekara, Joachim D Uys, Frederick P Bellinger, Scott C Steffensen
Methamphetamine (METH) is a drug with a high addictive potential that is widely abused across the world. While it is known that METH dysregulates both dopamine transmission and dopamine reuptake, the specific mechanism of action remains obscure. One promising target of METH is the sigma receptor, a chaperone protein located on the membrane of the endoplasmic reticulum. Using fast-scan cyclic voltammetry, we show that METH-enhancement of evoked dopamine release and basal efflux is dependent on sigma receptor activation...
November 29, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29165839/striatal-dopamine-in-parkinson-disease-a-meta-analysis-of-imaging-studies
#10
REVIEW
Valtteri Kaasinen, Tero Vahlberg
A meta-analysis of 142 positron emission tomography and single photon emission computed tomography studies that have investigated striatal presynaptic dopamine function in Parkinson disease (PD) was performed. Subregional estimates of striatal dopamine metabolism are presented. The aromatic L-amino-acid decarboxylase (AADC) defect appears to be consistently smaller than the dopamine transporter and vesicular monoamine transporter 2 defects, suggesting upregulation of AADC function in PD. The correlation between disease severity and dopamine loss appears linear, but the majority of longitudinal studies point to a negative exponential progression pattern of dopamine loss in PD...
December 2017: Annals of Neurology
https://www.readbyqxmd.com/read/29162745/does-sympathetic-dysfunction-occur-before-denervation-in-pure-autonomic-failure
#11
Ling Guo, Murray D Esler, Carolina Sari, Sarah Phillips, Elisabeth A Lambert, Nora E Straznicky, Gavin W Lambert, Susan J Corcoran
BACKGROUND: Pure autonomic failure (PAF) is a rare sporadic disorder characterised by autonomic failure in the absence of a movement disorder or dementia and is associated with very low plasma norepinephrine levels - suggesting widespread sympathetic denervation, however the underlying pathology remains poorly elucidated. We sought to correlate clinical and neurochemical findings with sympathetic nerve protein abundances, accessed by way of a forearm vein biopsy, in patients with PAF and in healthy controls and patients with multiple systems atrophy (MSA) in whom sympathetic nerves are considered intact...
November 21, 2017: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29153425/fluoroethoxy-1-4-diphenethylpiperidine-and-piperazine-derivatives-potent-and-selective-inhibitors-of-3-h-dopamine-uptake-at-the-vesicular-monoamine-transporter-2
#12
Emily R Hankosky, Shyam R Joolakanti, Justin R Nickell, Venumadhav Janganati, Linda P Dwoskin, Peter A Crooks
A small library of fluoroethoxy-1,4-diphenethyl piperidine and fluoroethoxy-1,4-diphenethyl piperazine derivatives were designed, synthesized and evaluated for their ability to inhibit [(3)H]dopamine (DA) uptake at the vesicular monoamine transporter-2 (VMAT2) and dopamine transporter (DAT), [(3)H]serotonin (5-HT) uptake at the serotonin transporter (SERT), and [(3)H]dofetilide binding at the human-ether-a-go-go-related gene (hERG) channel. The majority of the compounds exhibited potent inhibition of [(3)H]DA uptake at VMAT2, Ki changes in the nanomolar range (Ki = 0...
October 20, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29137186/dopaminergic-dysfunction-in-mammalian-dopamine-neurons-induced-by-simazine-neurotoxicity
#13
Xueting Li, Jia Yu, Jianan Li, Yanping Wu, Baixiang Li
Many studies have shown that the pollutant simazine (6-chloro-N,N'-diethyl-1,3,5-triazine-2,4-diamine), which has been overused, inhibits the proliferation of mammalian dopaminergic cells, and affects the developmental differentiation of mammalian dopaminergic neurons. However, few studies have shown the effects of simazine on dopaminergic metabolism in these cells. Therefore, we aim to examine the metabolic effects of simazine exposure in mouse dopaminergic progenitor neurons (MN9D) at different exposure times...
November 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29120264/treatment-options-for-chorea
#14
H Bashir, J Jankovic
Chorea is defined as jerk-like movements that move randomly from one body part to another. It is due to a variety of disorders and although current symptomatic therapy is quite effective there are few etiology- or pathogenesis-targeted therapies. The aim of this review is to summarize our own experience and published evidence in the treatment of chorea. Areas covered: After evaluating current guidelines and clinical practices for chorea of all etiologies, PubMed was searched for the most recent clinical trials and reviews using the term 'chorea' cross referenced with specific drug names...
January 2018: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/29115391/effect-on-the-dopaminergic-metabolism-induced-by-oral-exposure-to-simazine-during-the-prepubertal-period-in-rats
#15
Xueting Li, Jia Yu, Yanping Wu, Baixiang Li
The herbicide simazine is widely used in agricultural and non-agricultural fields. Studies have shown that simazine inhibits the proliferation of dopaminergic cells and affects the developmental differentiation of dopamine neurons. However, little is known about the effects of simazine on dopaminergic metabolism. Therefore, the present study examined the effects of simazine on Sprague‑Dawley (SD) rats from weaning to puberty (40 days exposure). Simazine was administered orally to SD rats at doses of 0, 12...
October 20, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29114100/successful-treatment-of-severe-tardive-dyskinesia-with-valbenazine-including-a-patient-s-perspective
#16
Richard C Josiassen, Dawn M Filmyer, Jack Gillean, Syed Sikandar Shah, Tyler E Dietterich, Rita A Shaughnessy
BACKGROUND Tardive dyskinesia (TD) is a chronic involuntary movement disorder frequently induced by dopamine receptor blockers, particularly first-generation antipsychotics. Until recently, management of TD was restricted to lowering the dose of the current medication, switching to another medication, or using off-label treatments with insufficient evidence of efficacy. Valbenazine, a vesicular monoamine transporter-2 (VMAT2) inhibitor, became the first drug to be approved by the FDA specifically for the treatment of TD...
November 8, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29080203/deutetrabenazine-a-review-in-chorea-associated-with-huntington-s-disease
#17
Young-A Heo, Lesley J Scott
Oral deutetrabenazine (Austedo™), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms associated with Huntington's disease (HD). In the pivotal 12-week phase III FIRST-HD trial (n = 90), deutetrabenazine, at doses titrated for optimal chorea control and tolerability (maintenance dosage range 12-48 mg/day), was significantly more effective for controlling chorea in HD patients than placebo...
November 2017: Drugs
https://www.readbyqxmd.com/read/29031997/a-six-year-longitudinal-pet-study-of-11-c-dtbz-binding-to-the-vmat2-in-monkey-brain
#18
Michael R Kilbourn, Robert A Koeppe
INTRODUCTION: The longitudinal reproducibility of in vivo binding potential measures for [(11)C]dihydrotetrabenazine ([(11)C]DTBZ) binding to the vesicular monoamine transporter 2 (VMAT2) site in primate brain was examined using a unique dataset of repeated control PET imaging studies. METHODS: Forty-one dynamic [(11)C]DTBZ PET studies were completed in a single rhesus monkey. Imaging equipment (microPET P4), personnel, radiotracer characteristics (injected mass amounts, molar activity) and image data analysis (BPND-Logan) were consistent throughout the entire sequence of PET studies...
September 5, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29024264/deutetrabenazine-for-tardive-dyskinesia-a-systematic-review-of-the-efficacy-and-safety-profile-for-this-newly-approved-novel-medication-what-is-the-number-needed-to-treat-number-needed-to-harm-and-likelihood-to-be-helped-or-harmed
#19
REVIEW
Leslie Citrome
OBJECTIVE: Deutetrabenazine is a deuterated formulation of tetrabenazine. The aim of this systematic review is to describe the efficacy, tolerability and safety of deutetrabenazine for the treatment of tardive dyskinesia (TD). DATA SOURCES: The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/ and http://www.clinicaltrials.gov, for the search terms 'deutetrabenazine' OR 'SD-809', and by also querying the EMBASE (Elsevier) commercial database for clinical poster abstracts, and by asking the manufacturer for copies of posters presented at congresses...
October 12, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28982631/effect-of-the-5%C3%AE-reductase-enzyme-inhibitor-dutasteride-in-the-brain-of-intact-and-parkinsonian-mice
#20
Nadhir Litim, Marc Morissette, Donatella Caruso, Roberto C Melcangi, Thérèse Di Paolo
Dutasteride is a 5alpha-reductase inhibitor in clinical use to treat endocrine conditions. The present study investigated the neuroprotective mechanisms of action of dutasteride in intact and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice using a low dose of MPTP not affecting motor activity modeling early stages of Parkinson's disease (PD). We hypothesized that dutasteride neuroprotection is due to altered steroids levels. Dutasteride pre-treatment prevented loss of striatal dopamine (DA) and its metabolite DOPAC...
November 2017: Journal of Steroid Biochemistry and Molecular Biology
keyword
keyword
82093
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"